<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03177863</url>
  </required_header>
  <id_info>
    <org_study_id>EX CIN 2 001</org_study_id>
    <nct_id>NCT03177863</nct_id>
  </id_info>
  <brief_title>Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age</brief_title>
  <acronym>EXCIN2</acronym>
  <official_title>Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age. A Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the Swedish organised cervical screening program precursors of cervical cancer are
      detected and treated. Most precursor lesions detected by screening heal spontaneously. Those
      who progress do it slowly. There are three levels from light; CIN1, moderate; CIN2 to severe;
      CIN3. Women with CIN3 are always treated, regardless of age, according to current clinical
      guidelines. Women with CIN2 who are below the age of 25 years are offered active expectance
      for up to two years because there is good evidence that they will spontaneously heal their
      lesions (regression) in 40-70% of the cases during that time.

      Method of treatment is today an excisional procedure of the cervix most often by Large loop
      excision of the transformation zone (LLETZ/LEEP) Treatment increases the risk of premature
      birth in a future pregnancy. In 2015 about 1800 excisional procedures of the transformation
      zone of the cervix were performed in the Västra Götalands regionen (VGR) om Sweden. The
      average age of first-time mothers in Sweden is rising and in 2014 it was 29 years. Postponed
      childbearing raises the question whether it is possible to refrain from surgery even for the
      group of women over 25 years old, with proven CIN2. Existing studies suggest that cure of
      CIN2 in the age group of and above 25 takes place in the same extent as under 25 years of
      age.There is lack of evidence concerning clinical follow-up.

      In a prospective multicenter clinical cohort study (observational study) with careful
      monitoring, the investigators will examine what proportion of CIN2 changes regress
      spontaneously within two years in women, 25-30 years old, and if human papillomavirus (HPV)
      type 16 may can be a marker for poor regression in this group. Instead of LLETZ, active
      expectance is offered to women this age with CIN2 in five gynecological clinics in VGR. The
      study protocol includes gynecologist visits every 6 months for two years, including cytology,
      colposcopy and directed biopsies of the cervix. Power calculation shows 160 women needs to be
      included, which is expected to occur within one year from the start.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Available in Swedish
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of regress</measure>
    <time_frame>24 months from date of visit when CIN2 was diagnosed</time_frame>
    <description>Proportion of women with CIN2 at inclusion who will regress to CIN1 or no evidence of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of regress for women with HPV16</measure>
    <time_frame>Proportion of women with CIN2 at inclusion who will regress to CIN1 or no evidence of disease</time_frame>
    <description>Proportion of women with CIN2 and HPV 16 at inclusion who will regress to CIN1 or no evidence of disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>CIN2</condition>
  <condition>Therapy</condition>
  <arm_group>
    <arm_group_label>Study cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy women 25 - 30 years of age with CIN2 who consent to inclusion and with no former history of CIN (any grade). The &quot;intervention&quot; is expectancy with clinical visits every 6 months. Women will leave study cohort if found with total regression (no CIN) or CIN3</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Expectancy</intervention_name>
    <description>Clinical monitoring. See arm description</description>
    <arm_group_label>Study cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CIN 2

          -  Written consent

        Exclusion Criteria:

          -  CIN (any grade) not resolved

          -  Former treatment of CIN

          -  Immunomodulating medication

          -  Pregnancy (at start of study)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Strander</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska Academy, Gothenburg University, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Björn Strander, PhD</last_name>
    <phone>+46704972226</phone>
    <email>bjorn.strander@rccvast.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katarina Kylebäck</last_name>
    <email>katarina.kyleback@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Södra Älvsborgs Sjukhus</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asmaa Soubhi Said, MD</last_name>
      <email>asmaa.soubhi.said@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kungshöjds gynekologmottagning</name>
      <address>
        <city>Göteborg</city>
        <zip>43350</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarina Kylebäck, MD</last_name>
      <phone>+46704244861</phone>
      <email>katarina.kyleback@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frölunda specialistsjukhus</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Greppe, MD</last_name>
      <phone>+463134229397</phone>
      <email>charlotte.greppe@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skaraborgs sjukhus, kvinnokliniken</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Björkenfeldt Havel, MD</last_name>
      <phone>+46500431433</phone>
      <email>christina.bjorkenfeldt@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norra Älvsborgs sjukhus, kvinnokliniken</name>
      <address>
        <city>Trollhättan</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Ekeryd-Andalen, MD</last_name>
      <phone>+46700823288</phone>
      <email>anne.ekeryd-andalen@vgregion.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013 Apr;121(4):829-46. doi: 10.1097/AOG.0b013e3182883a34.</citation>
    <PMID>23635684</PMID>
  </reference>
  <reference>
    <citation>Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P, Paraskevaidis E. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ. 2014 Oct 28;349:g6192. doi: 10.1136/bmj.g6192. Review.</citation>
    <PMID>25352501</PMID>
  </reference>
  <results_reference>
    <citation>Wilkinson TM, Sykes PH, Simcock B, Petrich S. Recurrence of high-grade cervical abnormalities following conservative management of cervical intraepithelial neoplasia grade 2. Am J Obstet Gynecol. 2015 Jun;212(6):769.e1-7. doi: 10.1016/j.ajog.2015.01.010. Epub 2015 Jan 9.</citation>
    <PMID>25582099</PMID>
  </results_reference>
  <results_reference>
    <citation>Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993 Apr;12(2):186-92. Review.</citation>
    <PMID>8463044</PMID>
  </results_reference>
  <results_reference>
    <citation>Discacciati MG, de Souza CA, d'Otavianno MG, Ângelo-Andrade LA, Westin MC, Rabelo-Santos SH, Zeferino LC. Outcome of expectant management of cervical intraepithelial neoplasia grade 2 in women followed for 12 months. Eur J Obstet Gynecol Reprod Biol. 2011 Apr;155(2):204-8. doi: 10.1016/j.ejogrb.2010.12.002. Epub 2010 Dec 28.</citation>
    <PMID>21193261</PMID>
  </results_reference>
  <results_reference>
    <citation>Guedes AC, Zeferino LC, Syrjänen KJ, Brenna SM. Short-term outcome of cervical intraepithelial neoplasia grade 2: considerations for management strategies and reproducibility of diagnosis. Anticancer Res. 2010 Jun;30(6):2319-23.</citation>
    <PMID>20651386</PMID>
  </results_reference>
  <results_reference>
    <citation>Ho GY, Einstein MH, Romney SL, Kadish AS, Abadi M, Mikhail M, Basu J, Thysen B, Reimers L, Palan PR, Trim S, Soroudi N, Burk RD; Albert Einstein Cervix Dysplasia Clinical Consortium. Risk factors for persistent cervical intraepithelial neoplasia grades 1 and 2: managed by watchful waiting. J Low Genit Tract Dis. 2011 Oct;15(4):268-75. doi: 10.1097/LGT.0b013e3182216fef.</citation>
    <PMID>21811178</PMID>
  </results_reference>
  <results_reference>
    <citation>Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009 Jan;113(1):18-25. doi: 10.1097/AOG.0b013e31818f5008.</citation>
    <PMID>19104355</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Björn Strander</investigator_full_name>
    <investigator_title>Senior researcher</investigator_title>
  </responsible_party>
  <keyword>neoplasm</keyword>
  <keyword>uterine cervix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

